Meeting
2019 Gastrointestinal Cancers Symposium
bTMB-High Basket trial: A multicenter phase II trial of nivolumab monotherapy in patients with advanced gastrointestinal cancers with high blood tumor mutational burden (bTMB).
Authors
Yoshiaki Nakamura
Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Yoshiaki Nakamura , Yoshito Komatsu , Ken Kato , Eiji Shinozaki , Hideaki Bando , Takeshi Kato , Tomohiro Nishina , Taito Esaki , Shogo Nomura , Gakuto Ogawa , Ayako Sugama , Miki Fukutani , Akihiro Sato , Justin Odegaard , Takeshi Kuwata , Kouji Matsushima , Tetsuya Nakatsura , Hiromichi Nakajima , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000033182
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr TPS179)
DOI
10.1200/JCO.2019.37.4_suppl.TPS179
Abstract #
TPS179
Poster Bd #
N11
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial.
First Author: Yoshiaki Nakamura
Poster
2023 ASCO Annual Meeting
Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).
First Author: Hiroya Taniguchi
Poster
2023 ASCO Annual Meeting
Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Katy Beckermann
Poster
2023 ASCO Annual Meeting
A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ).
First Author: Andrew H. Ko